1. Home
  2. APC vs GERN Comparison

APC vs GERN Comparison

Compare APC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ARKO Petroleum Corp. Class A Common Stock

APC

ARKO Petroleum Corp. Class A Common Stock

N/A

Current Price

$19.33

Market Cap

884.3M

Sector

Energy

ML Signal

N/A

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.50

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APC
GERN
Founded
2025
1990
Country
United States
United States
Employees
N/A
258
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
884.3M
808.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
APC
GERN
Price
$19.33
$1.50
Analyst Decision
Strong Buy
Hold
Analyst Count
4
3
Target Price
$21.75
$2.17
AVG Volume (30 Days)
210.6K
14.8M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
10.99%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.47
$26.91
Revenue Next Year
$4.20
$43.75
P/E Ratio
$25.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.08
$1.04
52 Week High
$21.72
$2.01

Technical Indicators

Market Signals
Indicator
APC
GERN
Relative Strength Index (RSI) 52.07 65.05
Support Level $17.55 $1.44
Resistance Level $19.43 $1.72
Average True Range (ATR) 0.75 0.09
MACD 0.09 0.03
Stochastic Oscillator 74.88 68.06

Price Performance

Historical Comparison
APC
GERN

About APC ARKO Petroleum Corp. Class A Common Stock

Arko Petroleum Corp is a fuel distribution company. It operates through three reportable segments: i) Wholesale: Distributes fuel to gas stations, sub-wholesalers, and bulk purchasers, typically under long-term contracts on a cost-plus or consignment basis. ii) Fleet Fueling: Operates proprietary and third-party cardlock locations serving commercial and municipal fleets, and earns commissions from proprietary fuel card sales. iii) GPMP: Supplies fuel to ARKO Retail Sites at cost plus a fixed margin, charges fixed fees to certain sites. The company generates the majority of revenue from the Wholesale segment.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: